Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27485912 | 0.94 | OPRK1 (0.57) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL7203881 | 0.92 | CA12 (0.63) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL18221882 | 0.85 | ALDH1A1 (0.74) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL7206800 | 0.84 | CA12 (0.54) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL7201652 | 0.83 | CNR2 (0.53) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL4581466 | 0.83 | ALDH1A1 (0.71) | CA12CA9MEN1KMT2AALDH1A1 | |
| SCHEMBL6355304 | 0.83 | ALDH1A1 (0.71) | CA12CA9MEN1KMT2AALDH1A1 | |
| SCHEMBL13426173 | 0.81 | OPRK1 (0.48) | OPRK1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL4119590 | 0.81 | ALDH1A1 (0.64) | OPRK1CA12CA9OPRM1ALDH1A1 | |
| SCHEMBL625181 | 0.80 | ALDH1A1 (0.84) | CA12CA9CYP1A2CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2011501-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use | Chelator LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1261349-B1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CHELATOR LLC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
| US-6881732-B2 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CHELATOR LLC (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1382332-A1 | Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent | Chelator LLC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CONCAT, LTD. A CALIFORNIA LIMITED PARTNERSHIP (US) | 2004-01-08 | — | — | US | disclosed |
| US-6583182-B1 | Atomic numbers 21-30 are components of enzymes required for nucleic acid replication; substituted polyaza compounds inhibit cell replication by decreaseing bioavailability of iron or copper | CHELATOR LLC | 2003-06-24 | — | — | US | disclosed |
| US-6469162-B1 | SUCH COMPOUNDS INHIBIT MAMMALIAN, BACTERIAL, AND FUNGAL CELL REPLICATION AND ARE USEFUL IN THE TREATMENT OF NEOPLASIA, INFECTION, INFLAMMATION, IMMUNE REPONSE, AND IN TERMINATION OF PREGNANCY | CONCAT, LTD. | 2002-10-22 | — | — | US | disclosed |
| US-6387891-B2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN COSMETICS AND PERSONAL CARE PRODUCTS, INHIBITION OF METALLOENZYMES, AND INHIBITION OF REPERFUSION INJURY | CONCAT, LTD. | 2002-05-14 | — | — | US | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| US-5846519-A | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | BRACCO DIAGNOSTICS INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5674470-A | Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | BRACCO DIAGNOSTICS INC. (US) | 1997-10-07 | — | — | US | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0292689-B1 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INT BV (NL) | 1996-07-31 | — | — | EP | disclosed |
| US-5474756-A | Chelate compound of a paramagnetic ion of lanthanide element | BRACCO INTERNATIONAL B.V. (NL) | 1995-12-12 | — | — | US | disclosed |
| EP-0232751-B1 | 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECANE AND ANALOGS | E.R. Squibb & Sons, Inc. (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0352218-A2 | Macrocyclic polyaza compounds containing rings with 5 or 6 members, methods for their preparation and pharmaceutical compositions containing same | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | MPO, LPO, SOD1 | OPRK1 2271/4885CA12 957/4885CA9 587/4885 |
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | SOD1, SLC39A11, SLC40A1 | OPRK1 1579/4885CA12 734/4885CA9 2355/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | OPRK1 1953/4885CA12 93/4885CA9 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.